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Abstract 
Purpose: Estimating risk of late distant recurrence (DR) is an important goal for 
managing women with hormone receptor positive breast cancer after 5 years’ 
endocrine treatment without recurrence. We develop and validate a simple 
clinicopathological tool (Clinical Treatment Score post-5 years (CTS5)) to estimate 
residual risk of DR after 5 years’ endocrine treatment. 
Patients and Methods: The ATAC dataset (N=4735) was used to create a 
prognostic score for post-5-year risk of DR. Validity of CTS5(ATAC) was tested in 
the BIG1-98 dataset (N=6711). Time to late DR, 5 years after finishing scheduled 
endocrine therapy, was the primary endpoint. Cox regression models estimated the 
prognostic performance of CTS5(ATAC).  
Results: CTS5(ATAC) was significantly prognostic for late DR in ATAC (HR=2.47 
(95% CI, 2.24-2.73), P<0.001), and the BIG1-98 validation cohort (HR=2.07 (1.88-
2.28), P<0.001). CTS5(ATAC) risk stratification defined in the training cohort as low 
(<5% DR risk,  years 5-10), intermediate (5-10%), or high (>10%) identified 43% of 
the validation cohort as low risk, with observed DR rate of 3.6% (95% CI 2.7-4.9) 
during years 5-10. 63% of node-negative were low risk with 3.9% (2.9-5.3) DR rate 
between years 5-10, and 24% with1-3 nodes positive were low risk with 1.5% (0.5-
3.8) DR rate between years 5-10. A final CTS5 for future use was derived from 
pooled data from ATAC and BIG1-98. 
Conclusion: CTS5 is a simple tool based on information that is readily available to 
all clinicians. CTS5 was validated as highly prognostic for late DR in the independent 
BIG 1-98 study. The final CTS5 algorithm identified 42% of women with <1% per 
year risk of DR who could be advised of the limited potential value of extended 
endocrine therapy.  
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Introduction 
 
Women with oestrogen receptor (ER) positive primary breast cancer are generally 
offered adjuvant endocrine therapy for 5 years. Over 50% of recurrences occur after 
that time and several studies indicate that extending treatment beyond 5 years can 
improve disease outcome [1-5]. This improvement is, however, relatively modest and 
extended therapy carries with it risk of adverse side-effects. Few tools have been 
developed for selecting patients as candidates for extended therapy or alternatively 
identifying those that might be spared it. One approach is to identify patients whose 
risk after 5 years is so low that any benefit would be outweighed by potential side 
effects.  
 
Clinicopathological parameters such as tumor size, nodal status, and histopathologic 
grade are routinely used to estimate risk of breast cancer recurrence at diagnosis: 
we have previously reported a Clinical Treatment Score that integrates these factors 
to estimate prognosis [6]. Some of these factors have also been reported to be 
associated with risk after 5 years; for example, we found that nodal status was a 
powerful prognostic marker for late recurrence [7, 8] whereas tumor size and 
particularly grade were less prognostic after 5 years. Recently an overview analysis 
of >60,000 women with ER+ disease who were scheduled to receive 5 years’ 
endocrine therapy and remained disease-free at 5 years, reported the subsequent 
risk of distant recurrence associated with standard clinicopathologic [9]. Even in 
patients with T1N0 disease the estimated risk of distant recurrence between years 5 
and 20 was 10% for low, 13% for intermediate, and 17% for high histologic grade, 
respectively. While these data unequivocally demonstrate the importance of these 
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clinicopathologic factors they include studies from 40 years ago possibly limiting their 
relevance for contemporary breast cancer patients. The data are also presented 
largely as categories (e.g. T1, T2) which limits their precise estimates of risk for 
individual patients to be made. Lastly, the large majority of the population was limited 
to 5 years’ treatment with tamoxifen, and did not allow for possible differences 
between tamoxifen and aromatase inhibitors (AIs) on long-term risk. 
  
We aimed to develop and test the validity of a simple prognostic tool to estimate risk 
of late distant recurrence (Clinical Treatment Score post-5-years (CTS5)) based on 
clinicopathological parameters measured in virtually all breast cancer patients at 
diagnosis. We used data from the Arimidex, Tamoxifen, Alone or in Combination 
(ATAC) trial [10] as the training set and from the (Breast International Group) BIG 1-
98 trial as the testing set [11].  
 
Methods 
Study populations 
The CTS5(ATAC) was trained using data from the ATAC trial (International Standard 
Randomised Controlled Trial, number ISRCTN18233230) in which postmenopausal 
women with ER-positive or ER-unknown early stage breast cancer were randomly 
assigned to receive 1mg/day anastrozole, 20mg/day tamoxifen, or the combination 
for five years [10]. The combination arm was discontinued after the first report of the 
trial results [12]. We included data from women with ER-positive breast cancer 
randomized to anastrozole alone or tamoxifen alone, who were distant recurrence-
free after 5 years’ follow-up, and for whom all clinicopathological data were available 
(N=4735) (Supplemental Figure 1). Median follow-up was 9.8 years. Data from BIG 
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1-98 (ClinicalTrials.gov, number NCT00004205) was used to validate the 
CTS5(ATAC). BIG 1-98 initially (1998-2000) randomly assigned postmenopausal 
women with hormone receptor-positive early stage breast cancer to receive 5 years’ 
2.5mg/day letrozole or 20mg/day tamoxifen. Later (1999-2003), sequential therapy 
was also randomly assigned (2 years’ letrozole followed by 3 years’ tamoxifen or 
opposite sequence) [11, 13]. Median follow-up was 8.1 years. For this analysis, all 
women were included who were distant recurrence-free at 5 years and for whom all 
clinicopathological data were available (N=6711) (Supplemental Figure 1). For both 
trials, women were included in the analysis whether or not they received 
chemotherapy.  
 
The prognostic value of the following variables for post-5-year (late) distant 
recurrence was determined by univariate Cox regression analyses: nodes, tumor 
size (mm), grade (1, 2, 3), age at start of endocrine therapy (years), and type of 
assigned endocrine treatment. Type of endocrine treatment was not significant for 
late distant recurrence in univariate analyses and therefore not included in the final 
model. The log-hazard was almost linear for five nodal status groups (nodes: 
negative, 1 positive, 2-3 positives, 4-9 positives, and >9 positives) but not for 
continuous tumor size alone. A negative quadratic term was therefore introduced 
and tumor size was capped at 30mm where the risk plateaued.  The final 
CTS5(ATAC) model included age as a continuous term, tumor size as a continuous 
term, quadratic tumor size, nodal status (five groups: 0=Negative; 1=1 positive; 2=2-
3 positive; 3=4-9 positive; 4= >9 positive) and grade (three groups: 1=low, 
2=intermediate, 3=high) and is given by:  
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CTS5(ATAC) = 0.471*nodes+0.980*(0.164*size-0.003*size2+0.312*grade+0.03*age) 
 
A shrinkage factor of 0.980 for the non-nodal part of the score was calculated using 
a nested Cox model [14] and applied to allow for the small amount of overfitting.  
 
Separate models developed for patients receiving chemotherapy or not did not 
perform significantly better for either group than a single model including all patients 
(data not shown). 
  
Statistical analysis 
Analyses were performed according to a pre-specified analysis plan, approved by 
both trial groups, and are summarised below. Full details are given in the 
supplementary file. The primary endpoint was time to distant recurrence. Distant 
recurrence was defined as metastatic disease, excluding contralateral disease, and 
loco-regional and ipsilateral recurrences. The endpoint was censored at last follow-
up visit or death before distant recurrence such that risk is a pure risk calculation 
ignoring deaths.  
 
Cox proportional hazard models were used to create the model in ATAC and the 
CTS5(ATAC) score was tested in BIG 1-98. Likelihood ratio statistics (LR-χ2) and 
Kaplan-Meier survival estimates with corresponding 95% confidence intervals were 
used to determine the prognostic performance of the CTS5(ATAC) in BIG 1-98. The 
5-10 year distant recurrence risk groups were determined in ATAC and defined as: 
low risk group <5%, intermediate risk group 5-10%, and high risk group >10%. To 
compare the prognostic performance of CTS5(ATAC) between ATAC and BIG 1-98 
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trials, CTS5(ATAC) was normalised to have unit variance and the hazard ratios 
(HRs) and associated 95% confidence interval (CI) were estimated from Cox 
models. All statistical analyses were two-sided, and p<0.05 was regarded as 
statistically significant. We also compared the newly developed CTS5(ATAC) to the 
published CTS (termed CTS0 below) that had been developed for estimating 
prognosis from the time of disease presentation [6]. All analyses were performed 
with STATA version 13.1 (College Station, Texas, USA). 
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Results 
The ATAC training set and the BIG 1-98 test set consisted of 4735 and 6711 
postmenopausal patients, respectively all of whom were assigned to receive a total 
of 5 years’ endocrine therapy (Table1). Women in the ATAC cohort were significantly 
older by an average of about 3 years, had more node-negative disease (68 vs 61%), 
more grade 3 tumors (25% vs 20%), and fewer women received adjuvant 
chemotherapy compared with women in the BIG 1-98 set (19.5% vs 24.2%). Tumor 
size was similar between the two trials. 330 (7.0%) late distant recurrences were 
recorded in the training set, with an annual hazard rate of 0.79% (95% CI 0.71-0.88). 
In BIG 1-98, a total of 370 (5.5%) late distant recurrences occurred with an annual 
hazard rate of 0.66% (95% CI 0.60-0.73) which was significantly lower than in ATAC 
(P=0.014) (Table 1). 
 
Training set (ATAC) 
Supplemental Table 1 shows the comparisons of the published CTS0 [6] with the 
CTS5(ATAC) for the prediction of late distant recurrence between years 5 and 10. 
The CTS5(ATAC) provided significantly more prognostic information compared to 
the CTS0 (CTS5(ATAC): LR-χ2=308.6 (5df); CTS0: LR-χ2=285.0 (9df)) and larger 
effect sizes were observed (HR=2.47 vs. HR=2.04, respectively). CTS5(ATAC) was 
slightly more prognostic in chemotherapy-free women compared to those who 
received chemotherapy (HR=2.50 (2.22-2.81) vs. HR=2.39 (1.94-2.95)) but the 
interaction with chemotherapy use was not significant (P=0.76).  
 
The prognostic value of CTS5(ATAC) for risk of distant recurrence (±95% CI) 
between years 5 and 10 is shown in Figure 1a for the whole population and in Figure 
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1b for the node-positive and node-negative populations separately. Cut-offs in the 
ATAC population to separate low, intermediate and high-risk populations were 4.35 
and 5.02, respectively (Figure 1a). As expected, the majority but not all of the low-
risk patients were node negative and conversely the majority of the high-risk were 
node-positive (Figure 1b).  
 
Overall, 42.0% were categorised as low risk, 31.3% as intermediate, and 26.7% as 
high risk of developing a late distant recurrence (Table 2). Those categorised into the 
low risk group had a mean 5-10 year distant recurrence risk of 2.5% (1.8-3.4) 
compared to 7.7% (6.3-9.5) for intermediate and 20.8% (18.2-23.6) for high-risk 
groups (Figure 3). Those being intermediate or high risk had a 3.42-fold (CI=2.37-
4.95) and 9.43-fold (CI=6.71-13.25), respectively, higher risk of late distant 
recurrence than the low-risk group. Notably only 2/133 patients with 1-3 nodes 
positive and categorised as low risk had a recurrence between years 5 and 10 
(Table 2). Virtually all patients with 4 or more nodes positive were categorised as 
high risk. About one-fifth of patients with 2 or 3 nodes positive had risk categorised 
as low or intermediate risk while 42.9% with 1 node positive were categorise as high 
risk. Only 57.7% of node-negative patients were categorised as low risk. 
 
Validation set (BIG 1-98) 
CTS5(ATAC) performed substantially better in the validation BIG 1-98 cohort than 
CTS0 (CTS5(ATAC): LR-χ2=212.1 (1df) vs. CTS0: LR-χ2=184.5 (1df)). CTS5(ATAC) 
was significantly prognostic in women who did not receive chemotherapy (HR=2.20 
(1.96-2.47), P<0.001; LR-χ2=168.7 (1df)), and more so compared to those who did 
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(HR=1.76 (1.46-2.13), P<0.001; LR-χ2=34.7 (1df)) (Supplemental Table 1) but the 
interaction with chemotherapy was not statistically significant (p=0.06).  
 
The number of observed distant recurrences was compared with those expected by 
CTS5(ATAC) in deciles of risk for node-negative and node-positive separately 
(Figure 2a and b). In each case there were no significant differences between the 
observed and expected for any of the deciles. The correlation (r) between the 
observed versus expected across the deciles was 0.89 for node-negative and 0.95 
for node-positive. Using the CTS0 a number of deciles showed significant χ2-values 
(Supplementary Figure 2) and the r-values were also lower being 0.78 and 0.87, 
respectively. Concordance between the estimated and actual distant recurrence 
rates was also shown to be better with CTS5 using Harell’s C-index: CTS5(ATAC), 
0.712; CTS0 0.641. 
 
We used pre-defined cut-off points of 4.35 and 5.02 from ATAC to determine risk 
groups for late distant recurrence in BIG 1-98 (Figure 1). These cut-points 
intersected the risk curves for BIG1-98 at 5.4% and 9.9% for node negative patients 
and 5.5% and 9.5% for node-positive patients, respectively and therefore were 
strongly validated by this test set. The distribution of patients into low, intermediate 
and high risk groups was also very similar in the BIG 1-98 dataset to that observed in 
the training set (Table 2). The mean 5-10 year distant recurrence risk of patients in 
BIG 1-98 in those 3 categories was 3.6% (2.7-4.9), 6.9% (5.9-8.5), and 17.3% (14.8-
20.1), respectively (Table 2, Figure 3). Thus for each category the actual mean risk 
for each category fitted well with that of the predicted risk. The curves for node-
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negative and node positive women were almost identical in the CTS5(ATAC) regions 
of overlap in BIG 1-98. 
 
Significant separation between low versus intermediate risk groups (HR=2.19 (1.61-
2.98)) and low versus high risk groups (HR=5.33 (4.02-7.07)) were observed (Figure 
3). Notably only 4/304 patients with 1-3 nodes positive and categorised as low risk 
had a recurrence between years 5 and 10. As with the ATAC dataset, in BIG 1-98 
virtually all patients with 4 or more nodes positive were categorised as high risk 
(Table 2). The distribution of patients in the risk categories across histological grades 
and across the nodal categories was similar between ATAC and BIG 1-98. Again, 
about one-fifth of patients with 2 or 3 nodes positive had risk categorised as low or 
intermediate risk but a somewhat smaller proportion of patients with 1 node positive 
were categorise as high risk (29.7% vs 42.9%). In BIG 1-98 62.5% of node-negative 
patients was categorised as low risk compared with 57.7% in ATAC. 
 
Combined ATAC and BIG 1-98 sets 
To increase the precision of the risk estimates we combined the ATAC and BIG 1-98 
datasets such that new coefficients were fitted using the same variables as in the 
training or validation cohorts. The final CTS5 is represented by the following model:   
CTS5=0.438*nodes+0.988*(0.093*size-0.001*size2+0.375*grade+0.017*age). 
The relationship between the final CTS5 and risk of distant recurrence is shown in 
Figure 4 with a table of CTS5 values that relate to one-unit intervals of distant 
recurrence risk. New cut-off points for low (CTS5<3.13), intermediate (3.13 to 3.86), 
and high risk (>3.86) groups were derived from this final model. An example of the 
calculation of CTS5 and the associated risk estimate is given in Figure 4. 
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Discussion 
Over the last 3 decades there have been major increases in invasive breast cancer 
incidence in western countries; in the US it is estimated that over 250,000 women 
will be diagnosed with invasive breast cancer in 2017 [15], the large majority being 
cases localised to the breast. About 80% of cases are now diagnosed as ER-positive 
and almost all of these are prescribed 5-years’ adjuvant endocrine therapy. While 
such treatment markedly reduces mortality (e.g. by about 30% with 5 years’ 
tamoxifen and about 40% with an AI in postmenopausal women) recurrences 
continue to occur after the 5 years’ treatment has ceased. The observations that 
these events can be decreased by continued treatment [1, 2, 16] means that 
decisions about whether to continue with therapy or not at 5 years are at the 
forefront of patient management at that time. We expect that the CTS5 tool reported 
and validated here will prove helpful to oncologists and patients in making a decision 
about continued treatment. The integration of clinical pathologic features that are 
measured in all patients at diagnosis should mean that risk is calculable at little 
expense globally: the Table in Figure 4 will allow a direct readout and an on-line tool 
will be provided to facilitate estimates of continuous risk. 
 
Strengths of the study include its use of two large sets of registration standard 
randomized clinical trial data with detailed clinical follow-up for 10 years. The ATAC 
training set included the AI, anastrozole, as well as tamoxifen as adjuvant treatment, 
and although the specific endocrine adjuvant therapy did not feature in the algorithm, 
this allowed us to infer that the score is valid for both tamoxifen and AI treated 
patients. This is consistent with the overview analysis of AIs versus tamoxifen [17]. 
Median five-year follow-up for the two trial combined occurred about 12 years ago. It 
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is therefore possible that our risk estimates may not accurately reflect those of 
current patients reaching 5 years. However, the only major changes to the 
management of primary ER-positive breast cancer since the completion of 
recruitment to ATAC and BIG1-98 has been the introduction of trastuzumab for 
patients with HER2+ disease. The CTS5 should be applied with caution in such 
patients until validated specifically for that population.  All patients in the two cohorts 
were postmenopausal at diagnosis. Although risk of distant recurrence post-5 years 
has been reported to be similar across age groups other than for the small group of 
patients diagnosed <35 years of age [9] the present  algorithm cannot be extended 
to  premenopausal patients without further validation.  
 
Neither trial collected complete information on the use of extended adjuvant 
endocrine therapy. However, the first significant data supporting the use of an AI 
after tamoxifen [1] emerged close to the end of the treatment period for the trials and 
we estimate that <1% of tamoxifen treated patients in ATAC and <5% in BIG 1-98 
received such extended therapy. This would be expected to have minimal impact on 
our estimates of risk when extended therapy is not used. 
 
Also similar to the EBCTCG paper we found that whether or not patients had 
received chemotherapy at presentation had no significant impact on residual risk of 
recurrence when taking the other factors into account. This may relate in part to the 
observation that the bulk of the benefit from adjuvant chemotherapy is shown over 
the first 5 years follow-up [18].  
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The categories of low, intermediate and high risk were chosen to be closely parallel 
to those defined by several molecular profiling tools for managing ER-positive breast 
cancer patients [19-21]. However, those tools are applied immediately after surgery 
largely for the decision to give adjuvant chemotherapy: what is considered low or 
high risk for that may not be the same as when considering the appropriateness of 
extended adjuvant therapy. For discussion with individual patients whose 
preferences for continuing or ceasing endocrine therapy at 5 years is likely to vary 
markedly, the use of a continuous risk estimate from the CTS5 is likely to be more 
informative than the categorical estimates (low, intermediate and high) used here for 
illustrative and comparative purposes. 
 
The agreement between the ATAC and BIG1-98 data was almost complete within 
the low and intermediate risk categories but somewhat less beyond the 
intermediate/high cut-off. Thus the instrument may be used with greatest confidence 
for defining 5-10 years distant recurrence risk when less than 10% and will be of 
greatest use in assessing the potential value of extended therapy on the basis of risk 
estimates below that level. 
 
The current report deals only with clinicopathologic profiles. Multigene expression 
profiles have significantly increased the ability to predict distant recurrence over 10 
years after diagnosis in ER-positive breast cancer [22]. Several of these signatures 
such as the Oncotype Dx Recurrence Score [23], PAM50-based Prosigna Risk of 
Recurrence Score [19, 24], Breast Cancer Index [25, 26], EndoPredict [20, 27, 28], 
and the NKI 70-gene signature [29] are commercially available and endorsed by 
several guidelines [30-33]. Although a number of them estimate risk of late as well as 
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early recurrence, these tests were developed to manage breast cancer patients at 
diagnosis and have not been calibrated for application 5 years after diagnosis. Over 
the first 10 years of follow-up clinicopathologic and molecular factors have nearly 
completely independent prognostic value and their optimal use for prognosis 
requires their integration [34]. It is near certain that the same is true for the 5-10 year 
period. The CTS5 provides a straightforward starting point for combining with 
molecular scores. 
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Legends to Figures: 
 
Figure 1: a). Predicted distant recurrence risk (%) in years 5-10 since randomization 
(start of adjuvant endocrine therapy) for ATAC trial overall population. b). Predicted 
distant recurrence risk (%) in years 5-10 since randomization (start of adjuvant 
endocrine therapy) for ATAC node-negative and node-positive patients. Solid red 
lines indicate cut-off points for risk groups. ATAC=Arimidex Tamoxifen Alone or 
Combination, CTS=Clinical Treatment Score, DR=Distant Recurrence. 
 
Figure 2: Observed versus expected number of events and Chi-square values in the 
BIG1-98 trial according to deciles of CTS5(ATAC) for node-negative and node-
positive patients.  
 
Figure 3: Kaplan-Meier curves and 5-10 year DR rates since randomization for the 
overall population according to trial (solid lines = ATAC, dotted lines = BIG 1-98). 
ATAC=Arimidex Tamoxifen Alone or Combination, BIG=Breast International Group, 
DR=Distant Recurrence. 
 
Figure 4: Predicted 5-10 year DR risk (%) since randomization and CTS5 values for 
the combined data set. Solid red lines indicate cut-off points for risk groups. 
CTS=Clinical Treatment Score, DR=Distant Recurrence. The arrow shows the CTS5 
and equivalent 5-10 year risk of a patient with a 12mm, node negative, grade 2 and 
54 years of age. Using the formula [CTS5=0.438*nodes+0.988*(0.093*size-
0.001*size2+0.375*grade+0.017*age)] her CTS5 is 2.61 and her 5-10 year risk of 
distant recurrence is 3%. 
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Table 1: Patient and tumor characteristics according to trial of patients who are 
distant-recurrence free at 5 years after randomization (start of adjuvant endocrine 
therapy). ATAC=Arimidex Tamoxifen Alone or Combination, BIG=Breast 
International Group, IQR=Interquartile range, mm=millimetre, CI=Confidence 
Intervals  
 
 ATAC 
 (N=4735) 
BIG 1-98  
(N=6711) 
P-value 
Age (years), median (IQR) 64 (57-71) 61 (56-67) <0.001 
Nodal status (number of 
positive nodes) 
   
 Negative 3219 (68.0%) 4090 (60.9%)  
 1 643 (13.6%) 1164 (17.3%)  
 2-3 523 (11.1%) 780 (11.6%)  
 4-9 277 (5.9%) 506 (7.5%)  
 9+ 73 (1.5%) 171 (2.6%)  
   P-trend<0.001 
Grade    
Well 1149 (24.3%) 1524 (22.7%)  
Intermediate 2387 (50.4%) 3828 (57.0%)  
Poor 1199 (25.3%) 1359 (20.3%)  
   P-trend=0.007 
Tumor size     
<10mm 864 (19.7%) 1172 (17.5%)  
10-20mm 2356 (49.8%) 3206 (47.8%)  
20-30mm 1028 (21.7%) 1571 (23.4%)  
>30mm 487 (10.3%) 762 (11.4%)  
   P-trend=0.44 
Chemotherapy 923 (19.5%) 1627 (24.2%) <0.001 
Treatment    
Tamoxifen 5 years 2374 (50.1%) 1989 (29.6%)  
Anastrozole or Letrozole 5 years 2361 (49.9%) 2042 (30.4%)  
2 years Letrozole/3 Years 
Tamoxifen 
- 1335 (19.9%)  
2 years Tamoxifen/3 Years 
Letrozole 
- 1345 (20.0%)  
Distant recurrence (>5 years) 
Annual rate % (95% CI) 
330 (7.0%) 
0.79% (0.71-0.88) 
370 (5.5%) 
0.66% (0.60-0.73) 
 0.014 
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Table 2: Distribution of the risk categories in the ATAC and BIG 1-98 cohorts 
according to tumor size, grade and nodal involvement. ATAC=Arimidex Tamoxifen 
Alone or Combination, BIG=Breast International Group, mm=millimetre. 
 ATAC  
  
Low risk (N=1989, 
42.0%) 
Intermediate risk 
(N=1484, 31.3%) 
High risk 
(N=1262, 
20.7%) 
Total 
(N=4735) 
Size      
 <10mm 808 (40.6%) 41 (2.8%) 15 (1.2%) 864 
 10-20mm 1082 (54.4%) 872 (58.8%) 402 (31.9%) 2356 
 >20mm 99 (5.0%) 571 (38.5%) 845 (67.0%) 1515 
Grade     
Well 806 (70.1%) 235 (20.58%) 108 (9.4%) 1149 
Intermediate 952 (39.9%) 861 (36.1%) 574 (24.0%) 2387 
Poor 231 (19.3%) 388 (32.4%) 580 (48.4%) 1199 
Nodal 
involvement 
    
 None 1856 (57.7%) 1138 (35.4%) 225 (7.0%) 3219 
 1 node 112 (17.4%) 255 39.7%) 276 (42.9%) 643 
 2-3 nodes 21 (4.0%) 84 (16.1%) 418 (79.9%) 523 
 4-9 nodes 0 6 (2.2%) 271 (97.8%) 277 
 >9 nodes 0 1 (1.4%) 72 (98.6%) 73 
 BIG 1-98  
  
Low risk (N=2861, 
42.6%) 
Intermediate risk 
(N=2136, 31.8%) 
High risk 
(N=1714, 
25.5%) 
Total 
(N=6711) 
Size     
 <10mm 1081 (37.8%) 65 (3.0%) 26 (1.5%) 1172 
 10-20mm 1585 (55.4%) 1103 (51.6%) 518 (30.2%) 3206 
 >20mm 195 (6.8%) 968 (45.3%) 1170 (68.3%) 2333 
Grade     
Well 1077 (70.7%) 308 (20.2%) 139 (9.1%) 1524 
Intermediate 1575 (41.1%) 1301 (34.0%) 952 (24.9%) 3828 
Poor 209 (15.4%) 527 (38.8%) 623 (45.8%) 1359 
Nodal 
involvement 
    
 None 2555 (62.5%) 1398 (34.2%) 137 (3.3%) 4090 
 1 node 277 (23.8%) 541 (46.5%) 346 (29.7%) 1164 
 2-3 nodes 27 (3.5%) 175 (22.4%) 578 (74.1%) 780 
 4-9 nodes 2 (0.4%) 21 (4.2%) 483 (95.5%) 506 
 >9 nodes 0 1 (0.6%) 170 (99.4%) 171 
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